Drug Discoveries and Therapeutics最新文献_第2页

Emulsification-based liposomal formulation of gallic acid and curcumin as potent topical antioxidants. 没食子酸和姜黄素作为有效的局部抗氧化剂的乳化型脂质体配方。

IF 1.9

Drug Discoveries and Therapeutics Pub Date : 2025-03-06 Epub Date: 2025-02-26 DOI: 10.5582/ddt.2025.01000

Takron Chantadee, Siripat Chaichit, Kanokwan Kiattisin, Worrapan Poomanee, Siriporn Okonogi, Pimpak Phumat

{"title":"Emulsification-based liposomal formulation of gallic acid and curcumin as potent topical antioxidants.","authors":"Takron Chantadee, Siripat Chaichit, Kanokwan Kiattisin, Worrapan Poomanee, Siriporn Okonogi, Pimpak Phumat","doi":"10.5582/ddt.2025.01000","DOIUrl":"10.5582/ddt.2025.01000","url":null,"abstract":"Excessive free radicals in the skin cause oxidative stress, damaging cells and leading to aging, melasma, and inflammation. This study developed a liposome system for co-delivering antioxidants to enhance their efficacy in deeper skin layers. Four phenolic compounds were screened for antioxidant activity using DPPH, nitric oxide scavenging, and lipid peroxidation assays. Gallic acid and curcumin, showing the strongest activity, were selected for liposome encapsulation via an emulsification method, with particle size reduction by probe sonication. High-performance liquid chromatography (HPLC) was used for chemical analysis, and particle morphology was examined with transmission electron microscopy. Studies on skin penetration, retention, and release were conducted. The optimized liposome (LP4) had a small particle size (< 150 nm), an unilamellar structure, and high entrapment efficiency (99% gallic acid and 92% curcumin). LP4 promoted effective skin retention of curcumin with slow penetration, while the release of gallic acid and curcumin from LP4 followed a Higuchi kinetic model and Zero-order kinetic model, respectively. This delivery system demonstrates potential for targeted antioxidant delivery, offering enhanced protection against oxidative damage in the skin.","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"38-48"},"PeriodicalIF":1.9,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Human gut associated Bacteroides and Akkermansia bacteria exhibit immunostimulatory activity in the silkworm muscle contraction assay. 在家蚕肌肉收缩试验中，人类肠道相关拟杆菌和阿克曼氏菌表现出免疫刺激活性。

IF 1.9

Drug Discoveries and Therapeutics Pub Date : 2025-03-06 Epub Date: 2025-02-27 DOI: 10.5582/ddt.2025.01001

Fumiaki Tabuchi, Chie Kano, Tatsuhiko Hirota, Tomomasa Kanda, Kazuhisa Sekimizu, Atsushi Miyashita

{"title":"Human gut associated Bacteroides and Akkermansia bacteria exhibit immunostimulatory activity in the silkworm muscle contraction assay.","authors":"Fumiaki Tabuchi, Chie Kano, Tatsuhiko Hirota, Tomomasa Kanda, Kazuhisa Sekimizu, Atsushi Miyashita","doi":"10.5582/ddt.2025.01001","DOIUrl":"10.5582/ddt.2025.01001","url":null,"abstract":"The immunoregulatory activity of human gut bacteria has attracted attention in recent years. To assess the innate immune-stimulatory activity of various samples in vivo efficiently, we previously introduced a silkwormbased assay as a novel alternative method. The method has been used for over a decade to screen for substances with potential physiological activity. In this study, we prepared heat-killed cells of four strains of human gut bacteria (Bacteroides ovatus, B. thetaiotaomicron, B. uniformis, and Akkermansia muciniphila) and assessed their innate immune-stimulatory activity within the silkworm model. Our findings indicate that the sample from either B. ovatus or B. thetaiotaomicron has immunostimulatory activity in the silkworm, in contrast to B. uniformis and A. muciniphila. Moreover, a pathogenicity assessment using the silkworm infection model was conducted to determine the safety of these bacterial strains for human consumption when considered as food ingredients. None of the four gut bacterial strains exhibited pathogenic effects in silkworms, with Pseudomonas aeruginosa serving as a positive control of the pathogenicity test. These results suggest that the silkworm-based assay can distinguish between the immunostimulatory effects of different human gut microbes and may enhance the safety evaluation of microbial ingredients.","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"74-79"},"PeriodicalIF":1.9,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Decreased serum calcium levels predict severe complications after initial diagnosis in patients with acute type B aortic dissection: A retrospective cohort study. 急性B型主动脉夹层患者初始诊断后血清钙水平降低可预测严重并发症：一项回顾性队列研究。

IF 1.9

Drug Discoveries and Therapeutics Pub Date : 2025-03-06 Epub Date: 2025-02-26 DOI: 10.5582/ddt.2025.01002

Fangzheng Meng, Liang Fang, Jing Zhou, Yiyuan Zhou, Junfeng Zhao, Ling Wang

{"title":"Decreased serum calcium levels predict severe complications after initial diagnosis in patients with acute type B aortic dissection: A retrospective cohort study.","authors":"Fangzheng Meng, Liang Fang, Jing Zhou, Yiyuan Zhou, Junfeng Zhao, Ling Wang","doi":"10.5582/ddt.2025.01002","DOIUrl":"10.5582/ddt.2025.01002","url":null,"abstract":"This study sought to investigate the temporal variations in serum calcium concentrations among patients with acute type B aortic dissection (ATBAD) following initial diagnosis, document the incidence of severe complications, and evaluate their potential associations. In this retrospective analysis, we examined 42 consecutive patients diagnosed with ATBAD at Zhejiang Hospital between April 2019 and April 2024. Serum-ionized calcium levels were measured at admission and 24 hours post-admission. Based on changes in calcium levels, patients were categorized into either the elevated or decreased groups. Univariate and multivariate logistic regression analyses were performed to compare clinical characteristics and assess the incidence of severe complications following the initial diagnosis. The study further explored the association between 24-hour serum calcium levels, their dynamic changes, and the occurrence of severe complications in patients with ATBAD. The results showed that the decreased group had a significantly higher frequency of severe complications, including mortality, cardiac complications, acute renal failure, and organ hypoperfusion (P < 0.05), while no significant differences were observed for neurological or pulmonary complications (P > 0.05). Logistic regression revealed that a decline in serum calcium levels within 24 hours was an independent risk factor for severe complications (OR = 16.722, P = 0.03). The receiver operating characteristic (ROC) curve showed an area under the curve (AUC) of 0.864. Decreased serum calcium concentration is an independent predictor of severe complications in ATBAD patients, significantly associated with mortality, cardiac complications, acute kidney injury, and inadequate organ perfusion. No significant correlation with neurological and pulmonary complications was observed.","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"49-57"},"PeriodicalIF":1.9,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Isolation and characterization of phosphoglycerate kinase and creatine kinase from bighead carp (Aristichthys nobilis): Potential sources for antitumor agents. 鳙鱼磷酸甘油酸激酶和肌酸激酶的分离与鉴定：抗肿瘤药物的潜在来源。

IF 1.9

Drug Discoveries and Therapeutics Pub Date : 2025-03-06 Epub Date: 2025-02-26 DOI: 10.5582/ddt.2025.01003

Yue Gao, Wanying Liu, Qing Yan, Chunlei Li, Mengke Gu, Sixue Bi, Weiming Zheng, Jianhua Zhu, Liyan Song, Rongmin Yu

{"title":"Isolation and characterization of phosphoglycerate kinase and creatine kinase from bighead carp (Aristichthys nobilis): Potential sources for antitumor agents.","authors":"Yue Gao, Wanying Liu, Qing Yan, Chunlei Li, Mengke Gu, Sixue Bi, Weiming Zheng, Jianhua Zhu, Liyan Song, Rongmin Yu","doi":"10.5582/ddt.2025.01003","DOIUrl":"10.5582/ddt.2025.01003","url":null,"abstract":"Bighead carp (Aristichthys nobilis) has garnered significant attention due to its potential health benefits, yet its bioactive protein components remain largely unexplored. In this study, two proteins S3 and Z1 were isolated from Aristichthys nobilis using ammonium sulfate precipitation and serial column chromatography guided by their in vitro antitumor activity. Both proteins were found to be homogeneous in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with a purity exceeding 95% as confirmed by reverse-phase high performance liquid chromatography (RP-HPLC). Electrospray ionization tandem mass spectrometry (ESI-MS/MS) analysis revealed their precise molecular weights to be 44.335 kDa for S3 and 43.028 kDa for Z1. Their amino acid sequences were elucidated through tandem mass spectroscopy and transcriptome unigene analysis, identifying S3 as phosphoglycerate kinase and Z1 as creatine kinase. Furthermore, secondary structure was measured by circular dichroism and three-dimensional structure was predicted by modeling software. The antitumor potential of S3 was evaluated by an in vitro assay, yielding an IC50 value of 26.3 ± 2.9 μM against the HT-29 cell line. Z1 demonstrated antiproliferative activity in vitro with IC50 values of 21.8 ± 1.4, 22.3 ± 2.1, and 22.3 ± 2.5 μM against HT-29, HeLa, and HepG2 cell lines, respectively. Notably, Z1 was found to enhance glucose metabolism and significantly increase the production of lactic acid and CO2 in tumor cells. These findings suggest that bighead carp (A. nobilis) could serve as a promising source for both antitumor agents and functional food ingredients.","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"58-67"},"PeriodicalIF":1.9,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Suzetrigine: The first Nav1.8 inhibitor approved for the treatment of moderate to severe acute pain. Suzetrigine：首个获批用于治疗中度至重度急性疼痛的Nav1.8抑制剂。

IF 1.9

Drug Discoveries and Therapeutics Pub Date : 2025-03-06 Epub Date: 2025-02-27 DOI: 10.5582/ddt.2025.01010

Shasha Hu, Dong Lyu, Jianjun Gao

引用次数: 0

Characteristics and patterns of adverse event reports in the Japanese Adverse Drug Event Report database over two decades (2004-2023): Exploring findings on sexes and age groups. 日本药物不良事件报告数据库中二十年（2004-2023）不良事件报告的特征和模式：探讨性别和年龄组的发现。

IF 1.9

Drug Discoveries and Therapeutics Pub Date : 2025-03-06 Epub Date: 2025-02-26 DOI: 10.5582/ddt.2024.01090

Hiroyuki Tanaka, Masaki Takigawa, Naohito Ide, Toshihiro Ishii

{"title":"Characteristics and patterns of adverse event reports in the Japanese Adverse Drug Event Report database over two decades (2004-2023): Exploring findings on sexes and age groups.","authors":"Hiroyuki Tanaka, Masaki Takigawa, Naohito Ide, Toshihiro Ishii","doi":"10.5582/ddt.2024.01090","DOIUrl":"10.5582/ddt.2024.01090","url":null,"abstract":"Recently, increased attention has been paid to the consideration of individual characteristics, including sex and age, in the context of medication use and adverse events. However, the characteristics and patterns of adverse events reported in the Japanese Adverse Drug Event Report (JADER) database stratified by sex and age have not yet been clarified. This study aimed to clarify the characteristics and patterns of adverse event reports in the JADER database over a 20-year period (April 2004-March 2024). Data were stratified into 20 groups based on sex and age (aged 0-9 years, 10-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, 80-89 years, and ≥90 years). The female/male ratio of adverse event reports in JADER was 0.95. The largest group comprised males in their 70s. Adjusting for the proportion of adverse event reports in each group according to the demographic composition in 2015 highlighted that the reporting rates of adverse events were higher in people aged ≥70 years and that females aged 20-49 years reported more adverse events than males. Medical history, causative drugs, and adverse events reported to JADER were characterized by combinations of sex and age. Our results provide additional insights into the interpretation of previous studies using JADER. In addition, the results of this study will help understand the characteristics of adverse event reports contained in JADER and conduct appropriate subgroup and sensitivity analyses.","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"10-21"},"PeriodicalIF":1.9,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of etanercept biosimilar switching from etanercept reference product, using ultrasound and clinical data in outcomes of real world therapy (ESCORT-NGSK Study). 依那西普生物仿制药从依那西普参比产品转换的疗效，使用超声和真实世界治疗结果的临床数据（ESCORT-NGSK研究）。

IF 1.9

Drug Discoveries and Therapeutics Pub Date : 2025-03-06 Epub Date: 2025-02-26 DOI: 10.5582/ddt.2024.01088

Remi Sumiyoshi, Shin-Ya Kawashiri, Toshimasa Shimizu, Tomohiro Koga, Rieko Kiya, Shigeki Tashiro, Yurika Kawazoe, Shuntaro Sato, Yukitaka Ueki, Takahisa Suzuki, Masahiko Tsuboi, Yoshifumi Tada, Toshihiko Hidaka, Hirokazu Takaoka, Naoki Hosogaya, Hiroshi Yamamoto, Atsushi Kawakami

{"title":"Efficacy of etanercept biosimilar switching from etanercept reference product, using ultrasound and clinical data in outcomes of real world therapy (ESCORT-NGSK Study).","authors":"Remi Sumiyoshi, Shin-Ya Kawashiri, Toshimasa Shimizu, Tomohiro Koga, Rieko Kiya, Shigeki Tashiro, Yurika Kawazoe, Shuntaro Sato, Yukitaka Ueki, Takahisa Suzuki, Masahiko Tsuboi, Yoshifumi Tada, Toshihiko Hidaka, Hirokazu Takaoka, Naoki Hosogaya, Hiroshi Yamamoto, Atsushi Kawakami","doi":"10.5582/ddt.2024.01088","DOIUrl":"10.5582/ddt.2024.01088","url":null,"abstract":"This study aimed to investigate in detail the efficacy of switching from etanercept reference product (RP) to etanercept biosimilar in patients with rheumatoid arthritis (RA) under real-world clinical conditions using clinical indices and musculoskeletal ultrasound (MSUS). This interventional, multicenter, open-label, single-arm clinical trial involved 24- or 52-week follow-up. This study enrolled patients with RA who had been treated with etanercept-RP for ≥ 24 weeks, achieved clinical low disease activity (LDA) or remission, and switched from etanercept-RP to etanercept biosimilar. This study included 20 patients. Of the 17 patients, 16 (94.1%; 95% confidence interval [CI]: 71.3-99.9) remained in LDA/remission on DAS28-ESR at 24 weeks. The dose of 50 mg/week was reduced to 25 mg/week at 24 weeks, and LDA/remission was sustained until 52 weeks in 9 (81.8%, 95% CI: 48.2-97.7] of 11 participants. DAS28-ESR, DAS28-CRP, SDAI, and CDAI scores showed no apparent worsening. The median total PD score remained 0. The switch from etanercept-RP to etanercept biosimilar and subsequent dose reduction demonstrated favorable outcomes, including MSUS evaluation.","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"29-37"},"PeriodicalIF":1.9,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Baricitinib-loaded EVs promote alopecia areata mouse hair regrowth by reducing JAK-STAT-mediated inflammation and promoting hair follicle regeneration. baricitinib负载ev通过减少jak - stat介导的炎症和促进毛囊再生来促进斑秃小鼠毛发再生。

IF 1.9

Drug Discoveries and Therapeutics Pub Date : 2025-01-14 Epub Date: 2024-12-11 DOI: 10.5582/ddt.2024.01080

Haowen Tang, Fangfang Wang, Rui Yang, Ziqi Zhao, Ying Zhang, Li Yang, Bingmin Li

{"title":"Baricitinib-loaded EVs promote alopecia areata mouse hair regrowth by reducing JAK-STAT-mediated inflammation and promoting hair follicle regeneration.","authors":"Haowen Tang, Fangfang Wang, Rui Yang, Ziqi Zhao, Ying Zhang, Li Yang, Bingmin Li","doi":"10.5582/ddt.2024.01080","DOIUrl":"10.5582/ddt.2024.01080","url":null,"abstract":"Alopecia areata (AA) is a common and recurrent type of hair loss. Despite oral administration of baricitinib exerts a good effect on refractory AA, the long-term administration of baricitinib carries significant side effects, poor compliance, and the efficacy is difficult to maintain after drug withdrawal. Therefore, the exploration of a safe and effective local administration of baricitinib to treat AA is of great clinical importance. However, baricitinib has a large molecular weight and is barely soluble in water, while the hair follicle lies deep, thus conventional topical dosage forms are ineffective. This study investigated the efficacy of local injection of baricitinib-loaded mesenchymal stem cell exosomes (EVs) in the treatment of AA. First, we constructed baricitinib loaded EVs (EV-B) and established AA mouse model by intravenously injection with murine INF-γ according to previous literature reports. The therapeutic effects of EV-B on hair regrowth were recorded and the underlying mechanism was also analyzed by Luminex protein biochip test and western-blot. Compared to control group, the baricitinib, EV and EV-B groups exhibited improved hair coverage in the AA mouse model. Besides, EV-B group achieved the optimal effect. The underlying mechanism might be attributed to the improvement of drug delivery efficiency as well as the synergistic effect of EVs, leading to better inhibition of JAK-STAT pathway and upregulation of the Wnt/β-catenin pathway. Our findings proved the effectiveness of EV-B on the treatment of AA, and might provide a new therapeutic approach for AA in future clinical application.","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"368-374"},"PeriodicalIF":1.9,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of a simple high-performance liquid chromatography-ultraviolet detection method for selpercatinib determination in human plasma. 建立高效液相色谱-紫外检测法测定人血浆中selpercatinib。

IF 1.9

Drug Discoveries and Therapeutics Pub Date : 2025-01-14 Epub Date: 2024-12-08 DOI: 10.5582/ddt.2024.01076

Wataru Suzuki, Yoshito Gando, Takeo Yasu

{"title":"Development of a simple high-performance liquid chromatography-ultraviolet detection method for selpercatinib determination in human plasma.","authors":"Wataru Suzuki, Yoshito Gando, Takeo Yasu","doi":"10.5582/ddt.2024.01076","DOIUrl":"10.5582/ddt.2024.01076","url":null,"abstract":"Selpercatinib is a selective rearranged during transfection (RET) kinase inhibitor effective for the treatment of RET-positive non-small cell lung cancer, thyroid cancer, and other cancers. However, its clinical use requires careful management because of dose-dependent adverse effects and pharmacokinetic interactions. Given the multiple factors influencing selpercatinib blood levels, we hypothesized that establishing a therapeutic drug monitoring system for selpercatinib could help reduce adverse events and optimize efficacy. Therefore, we herein developed a high-performance liquid chromatography-ultraviolet (HPLC-UV) method for measuring selpercatinib blood levels to facilitate therapeutic drug monitoring in clinical practice. Proteins were precipitated with acetonitrile, and selpercatinib and the internal standard (gefitinib) were separated via HPLC-UV. The calibration curve was linear over 0.5-8.0 µg/mL with a coefficient of determination (r²) equaling 0.9996. Intra- and interday validation coefficients were both under 2.80%. The corresponding measurement precision ranged from - 1.50% to 12.60% and - 1.32% to 7.50%, respectively, with recoveries exceeding 94.43%. Thus, this study establishes a simple and sensitive method for quantifying selpercatinib in human plasma. Future studies will analyze plasma samples from patients treated with selpercatinib and utilize this method to explore the relationships among plasma concentration, efficacy, and adverse events to define the therapeutic concentration range.","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"387-390"},"PeriodicalIF":1.9,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Agarwood as a potential therapeutic for Alzheimer's disease: Mechanistic insights and target identification. 沉香作为阿尔茨海默病的潜在治疗药物：机制见解和靶点鉴定。

IF 1.9

Drug Discoveries and Therapeutics Pub Date : 2025-01-14 Epub Date: 2024-12-21 DOI: 10.5582/ddt.2024.01085

Ya-Nan Ma, Xiqi Hu, Kenji Karako, Peipei Song, Wei Tang, Ying Xia

{"title":"Agarwood as a potential therapeutic for Alzheimer's disease: Mechanistic insights and target identification.","authors":"Ya-Nan Ma, Xiqi Hu, Kenji Karako, Peipei Song, Wei Tang, Ying Xia","doi":"10.5582/ddt.2024.01085","DOIUrl":"10.5582/ddt.2024.01085","url":null,"abstract":"Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and functional impairments. Despite extensive research, its pathogenesis remains incompletely understood, and effective treatments are limited. This study explored the therapeutic potential of agarwood in AD by integrating network pharmacology, protein-protein interaction (PPI) network analysis, and single-cell expression analysis. The results revealed that agarwood compounds may modulate key inflammatory genes such as NFKB1, STAT1, and TLR4, alleviating neuroinflammation; enhance the expression of HSP90 and regulate KDR signaling to improve blood-brain barrier (BBB) integrity; and promote the activity of PTPN11 and CXCR4 to support oligodendrocyte precursor cell (OPC) repair and remyelination. Single-cell expression analysis highlighted cell-type-specific expression patterns, particularly in OPCs and endothelial cells, underscoring their relevance in AD pathology. Agarwood's multi-dimensional therapeutic potential positions it as a promising candidate for the development of novel AD treatments.","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"375-386"},"PeriodicalIF":1.9,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0